Company news

Schrodinger, Inc. news in 2025

Schrodinger, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

December 16, 2025

Schrödinger to Present at Jefferies London Healthcare Conference

November 5, 2025

Schrödinger Reports Third Quarter 2025 Financial Results

November 4, 2025

Schrödinger to Announce Third Quarter 2025 Financial Results on November 5

October 21, 2025

Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635c4

October 16, 2025

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

August 26, 2025

Schrödinger Announces Discontinuation of SGR-2921 Program

August 13, 2025

Schrödinger Reports Second Quarter 2025 Financial Results

August 6, 2025

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

July 24, 2025

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

July 16, 2025

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

June 26, 2025

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

June 11, 2025

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

May 28, 2025

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

May 28, 2025

Schrödinger to Present at Jefferies Global Healthcare Conference

May 21, 2025

Schrödinger Announces CFO Appointment

May 19, 2025

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

May 13, 2025

Schrödinger Reports Strong First Quarter 2025 Financial Results

May 6, 2025

Schrödinger to Present at BofA Securities 2025 Healthcare Conference

May 4, 2025

Schrödinger Presents New Preclinical Data at AACR Annual Meeting

April 27, 2025

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

April 22, 2025

Schrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

April 13, 2025

Schrödinger to Present Preclinical Data at AACR Annual Meeting

March 24, 2025

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

March 9, 2025

Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results

February 25, 2025

Schrödinger to Participate in Upcoming Investor Conferences

February 23, 2025

Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26

February 11, 2025

Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities

January 12, 2025

Calls in 2025

Decks in 2025